Physician profile
Meghan E Hunter
NPI 1174727705
$976.85
in general payments reported to CMS, 2019-2025
14 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2021: $59.64 · 2022: $125 · 2023: $171 · 2024: $180 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $395.40 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $138.91 | 2021-2025 | Vaxelis, Gardasil 9, M-M-R II |
| Ironshore Pharmaceuticals INC. | $77.33 | 2021-2022 | |
| Exact Sciences Corporation | $62.64 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $45.45 | 2019-2024 | Zepbound, Mounjaro |
| Abbott Laboratories | $43.71 | 2023-2025 | Proclaim, Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $38.93 | 2022 | |
| Sanofi Pasteur INC. | $38.79 | 2019 | |
| Abbvie INC. | $38.13 | 2024-2025 | |
| Glaxosmithkline, LLC. | $30.62 | 2023 | Shingrix |
| Hologic Sales and Service, LLC | $25.92 | 2025 | Aptima |
| Adlon Therapeutics L.P. | $15.52 | 2021 | |
| Acella Pharmaceuticals, LLC | $13.68 | 2025 | NP Thyroid 60 |
| Dynavax Technologies Corporation | $11.82 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.